Summary
- Kinnate Biopharma has filed to raise investment capital in a U.S. IPO.
- The firm is developing treatments for various cancers using a kinase inhibitor approach.
- KNTE has produced intriguing preclinical response results for its lead candidate.
- Looking for more investing ideas like this one? Get them exclusively at IPO Edge. Get started today »
Quick Take
Kinnate Biopharma (KNTE) has filed to raise $100 million in an IPO of its common stock, according to an S-1 registration statement.
The firm is a preclinical stage biopharma developing kinase inhibitor programs targeting difficult to treat cancers.
KNTE has produced intriguing results in preclinical studies for its lead candidate.
I’ll provide an update when we learn more about the IPO from management.
Company and Technology
San Diego, California-based Kinnate was founded to create its Kinnate Discovery Engine and focus its efforts on three patient populations with the following cancer characteristics:
1. Cancers contain known oncogenic drivers - gene mutations.
2. Cancers with 'genomically' well-characterized tumors that have intrinsic resistance to currently available treatments.
3. Cancers that have acquired resistance over the course of existing treatment therapy attempts.
Management is headed by president and CEO Mr. Nima Farzan, who has been with the firm since March 2020 and was previously an advisor to Emergent BioSolutions and MODA Pharmaceuticals.
Below is a brief overview video of kinase inhibitors and immunomodulatory drugs:
